Please assess the completion status of the following clinical trial:

Trial Title: Etanercept in New Onset Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females subjects with T1DM aged 3-18 years~* Positive GAD 65 and/or islet cell antibody~* HbA1c at diagnosis above 6%~* Insulin regimen with 3 injection of insulin daily (as described below)~* White blood count between 3,000-10,000 and platelets \> 100,000~* Normal ALT and AST, creatinine \< 1.8 mg/dl~* T1DM duration equal or less than 4 weeks~Exclusion Criteria:~* Infection requiring IV antibiotics at diagnosis or within past 14 days from study entry~* BMI over 85th percentile for age and gender~* Unstable household~* Unable to provide compliance with study drug, insulin and study visits,~* Evidence of psychiatric disease in the potential study subject and/or primary care taker~* And chronic diseases, including additional autoimmune disorders with the exception of euthyroid autoimmune thyroiditis

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 drug, 2 placebo (Type: EXPERIMENTAL): 1. Etanercept~2. Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).